Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - oral spray - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenindione -

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml; potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 91.84 mg/ml equivalent to amoxicillin 80 mg/ml potassium clavulanate 27.154 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 11.40 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml; potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - gargle - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat and mouth